Triflusal


Concise Prescribing Info
Indications/Uses
Prophylaxis of thromboembolic disorders.
Dosage/Direction for Use
Adult : PO Usual: 300-900 mg/day.
Dosage Details
Oral
Prophylaxis of thromboembolic disorder
Adult: Usual dose: 300-900 mg daily.
Administration
Should be taken with food.
Adverse Reactions
Nausea, vomiting, gastric and epigastric pain, erythema, conjunctival haemorrhage, epistaxis.
Action
Description: Triflusal, a derivative of salicylic acid, is an inhibitor of platelet aggregation. It inhibits platelet arachidonic metabolism and stimulates platelet cAMP production. Unlike aspirin, it does not increase bleeding time. It may also have neuroprotective effects as animal studies have shown that it blocks the biochemical pathway that leads to cell damage during ischemia in the nervous system.
Pharmacokinetics:
Absorption: Bioavailability: 83-100%. Peak plasma concentration: 0.88 hr (triflusal); 4.96 hr (HTB).
Distribution: Protein binding: extensive.
Metabolism: Rapidly metabolised by liver to active metabolite, 3-Hydroxy-4-trifluoro-methylbenzoic acid (HTB).
Excretion: Via urine as metabolites. Terminal half life: 0.53 hr (triflusal); 34.29 hr (HTB)
Disclaimer: This information is independently developed by MIMS based on Triflusal from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in